Search

Your search keyword '"Perna, Carla"' showing total 36 results
Start Over Author "Perna, Carla"
36 results on '"Perna, Carla"'

1. Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes

Author

Benafif, Sarah, Jones, Ann-Britt, Merson, Susan, Rageevakumar, Reshma, McGrowder, Eva, Tyler, Matthew, Cafferty, Fay, Hogben, Matthew, Hussain, Nafisa, Bancroft, Elizabeth, Reid, Alison, Wakerell, Sarah, Karlsson, Questa, Saunders, Edward, Whitmore, Ian, Sorensen, Karina Dalsgaard, Dennis, Nening, Black, Evie, Wood, Angela, Richards, Kate, Lees, Kathryn, Perna, Carla, Falconer, Alison, Mills, Jamie, Hughes, Robert, Kumar, Shiyam, Mikropoulos, Christos, Burnett, Stephanie, Attard, Gerhardt, Hall, Emma, Kote-Jarai, Zsofia, and Eeles, Ros

Published
2024
Full Text
View/download PDF

4. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Author

Jones, Elin, Hyde, Katherine, Glen, Hilary, Needleman, Sarah, McGovern, Ursula, Sheehan, Denise, Paisey, Sangeeta, Shaffer, Richard, Beresford, Mark, Malik, Zafar, Zarkar, Anjali, Porfiri, Emilio, Fackrell, David, Lee, Ling, Sreenivasan, Thiagarajan, Brock, Sue, Brown, Simon, Bahl, Amit, Smith-Howell, Mike, Woodward, Cathryn, Phan, Mau-Don, Mazhar, Danish, Narahari, Krishna, Tanguay, Jacob, Douglas, Fiona, Kumar, Anil, Hamid, Abdel, Ibrahim, Azman, Muthukumar, Dakshinamoorthy, Simms, Matthew, Worlding, Jane, Tran, Anna, Kagzi, Mohammed, Das, Prantik, Pezaro, Carmel, Sivoglo, Virgil, Masters, Benjamin, Keng-Koh, Pek, Manetta, Caroline, McLaren, Duncan, Gupta, Nishi, Boussios, Stergios, Taylor, Henry, Graham, John, Perna, Carla, Melcher, Lucinda, Grant, Warren, Sabharwal, Ami, Hofmann, Uschi, Dealey, Robert, McPhail, Neil, Brierly, Robert, Capaldi, Lisa, Sidek, Norma, Whelan, Peter, Robson, Peter, Falconer, Alison, Rudman, Sarah, Vivekanandan, Sindu, Mullessey, Vinod, Vilarino-Varela, Maria, Khoo, Vincent, Tipples, Karen, Afshar, Mehran, Brulinski, Patryk, Sangar, Vijay, Peedell, Clive, Azzabi, Ashraf, Hoskin, Peter, Mullassery, Viwod, Sundar, Santhanam, Khan, Yakhub, Conroy, Ruth, Protheroe, Andrew, Carser, Judith, Rogers, Paul, Tarver, Kathryn, Gibbs, Stephanie, Khan, Mohammad Muneeb, Hingorani, Mohan, Crabb, Simon, Alameddine, Manal, Bhalla, Neeraj, Hughes, Robert, Logue, John, Leaning, Darren, Vengalil, Salil, Ford, Daniel, Walker, Georgina, Shaheen, Ahmed, Khan, Omar, Chan, Andrew, Ahmed, Imtiaz, Hilman, Serena, Sayers, Ian, Nikapota, Ashok, Bloomfield, David, Porter, Tim, Joseph, Joji, Rentsch, Cyrill, Pereira Mestre, Ricardo, Roggero, Enrico, Beyer, Jörg, Borner, Markus, Strebel, Raeto, Berthold, Dominik, Engeler, Daniel, John, Hubert, Popescu, Razvan, Durr, Donat, Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Sachdeva, Ashwin, Jones, Craig, Hoyle, Alex, Cross, William, Jones, Robert J, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Gilson, Clare, Rush, Hannah, Abdel-Aty, Hoda, Amos, Claire L, Murphy, Claire, Chowdhury, Simon, Russell, J Martin, Parkar, Nazia, Pugh, Cheryl, Diaz-Montana, Carlos, Saxby, Helen, Pedley, Ian, O'Sullivan, Joe M, Birtle, Alison, Gale, Joanna, Srihari, Narayanan, Thomas, Carys, Wagstaff, John, Gray, Emma, Alzouebi, Mymoona, Parikh, Omi, Robinson, Angus, Montazeri, Amir H, Wylie, James, Cathomas, Richard, Brown, Michael D, Jain, Yatin, Dearnaley, David P, Mason, Malcolm D, Gilbert, Duncan, Langley, Ruth E, Millman, Robin, Matheson, David, Sydes, Matthew R, Brown, Louise C, Parmar, Mahesh K B, and James, Nicholas D

Published
2023
Full Text
View/download PDF

8. Salvage Radiotherapy

Author

Perna, Carla, Uribe, Jennifer, Uribe-Lewis, Santiago, Langley, Stephen E. M., Goonewardene, Sanchia S., editor, Persad, Raj, editor, Ventii, Karen, editor, Albala, David, editor, and Cahill, Declan, editor

Published
2021
Full Text
View/download PDF

9. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Author

Jones, Elin, Hyde, Katherine, Glen, Hilary, Needleman, Sarah, McGovern, Ursula, Sheehan, Denise, Paisey, Sangeeta, Shaffer, Richard, Beresford, Mark, Malik, Zafar, Zarkar, Anjali, Porfiri, Emilio, Fackrell, David, Lee, Ling, Sreenivasan, Thiagarajan, Brock, Sue, Brown, Simon, Bahl, Amit, Smith-Howell, Mike, Woodward, Cathryn, Phan, Mau-Don, Mazhar, Danish, Narahari, Krishna, Tanguay, Jacob, Douglas, Fiona, Kumar, Anil, Hamid, Abdel, Ibrahim, Azman, Muthukumar, Dakshinamoorthy, Simms, Matthew, Worlding, Jane, Tran, Anna, Kagzi, Mohammed, Das, Prantik, Pezaro, Carmel, Sivoglo, Virgil, Masters, Benjamin, Keng-Koh, Pek, Manetta, Caroline, McLaren, Duncan, Gupta, Nishi, Boussios, Stergios, Taylor, Henry, Graham, John, Perna, Carla, Melcher, Lucinda, Grant, Warren, Sabharwal, Ami, Hofmann, Uschi, Dealey, Robert, McPhail, Neil, Brierly, Robert, Capaldi, Lisa, Sidek, Norma, Whelan, Peter, Robson, Peter, Falconer, Alison, Rudman, Sarah, Vivekanandan, Sindu, Mullessey, Vinod, Vilarino-Varela, Maria, Khoo, Vincent, Tipples, Karen, Afshar, Mehran, Brulinski, Patryk, Sangar, Vijay, Peedell, Clive, Azzabi, Ashraf, Hoskin, Peter, Mullassery, Viwod, Sundar, Santhanam, Khan, Yakhub, Conroy, Ruth, Protheroe, Andrew, Carser, Judith, Rogers, Paul, Tarver, Kathryn, Gibbs, Stephanie, Khan, Mohammad Muneeb, Hingorani, Mohan, Crabb, Simon, Alameddine, Manal, Bhalla, Neeraj, Hughes, Robert, Logue, John, Leaning, Darren, Vengalil, Salil, Ford, Daniel, Walker, Georgina, Shaheen, Ahmed, Khan, Omar, Chan, Andrew, Ahmed, Imtiaz, Hilman, Serena, Sayers, Ian, Nikapota, Ashok, Bloomfield, David, Porter, Tim, Joseph, Joji, Rentsch, Cyrill, Pereira Mestre, Ricardo, Roggero, Enrico, Beyer, Jörg, Borner, Markus, Strebel, Raeto, Berthold, Dominik, Engeler, Daniel, John, Hubert, Popescu, Razvan, Durr, Donat, Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Cross, William, Jones, Robert J, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Amos, Claire L, Atako, Nafisah, Pugh, Cheryl, Buckner, Michelle, Chowdhury, Simon, Russell, J Martin, Gilson, Clare, Rush, Hannah, Bowen, Jo, Lydon, Anna, Pedley, Ian, O'Sullivan, Joe M, Birtle, Alison, Gale, Joanna, Srihari, Narayanan, Thomas, Carys, Wagstaff, John, Gray, Emma, Alzoueb, Mymoona, Parikh, Omi, Robinson, Angus, Syndikus, Isabel, Wylie, James, Thalmann, George, de Bono, Johann S, Dearnaley, David P, Mason, Malcolm D, Gilbert, Duncan, Langley, Ruth E, Millman, Robin, Matheson, David, Sydes, Matthew R, Brown, Louise C, Parmar, Mahesh K B, and James, Nicholas D

Published
2022
Full Text
View/download PDF

10. The Landscape of Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Cancer (RCC).

Author

Moreno-Olmedo, Elena, Sabharwal, Ami, Das, Prantik, Dallas, Nicola, Ford, Daniel, Perna, Carla, and Camilleri, Philip

Subjects
KIDNEY tumors, KIDNEY abnormalities, CANCER patient medical care, RADIOSURGERY, RADIO frequency therapy, PATIENT care, HEMODIALYSIS, RENAL cell carcinoma, ALTERNATIVE medicine, CELL death, CATHETER ablation, TUMOR classification, HEALTH care teams
Abstract

Simple Summary: RCC has traditionally been considered radioresistant, with surgery being the gold standard for primary localized RCC. However, not all patients are suitable for surgery and percutaneous, non-surgical options are invasive, with significant limitations. SABR is a non-invasive advanced RT technique that delivers high doses accurately. Growing evidence supports SABR as a definitive alternative therapy for medically inoperable patients, those who decline surgery, are unfit for invasive ablation, or are at high-risk of requiring postoperative dialysis. SABR has shifted the renal radioresistance paradigm, widening the therapeutic window. Additionally, SABR is increasingly used for locally recurrent, oligoprogressive, and oligometastatic disease. This review aims to support the use of SABR across various stages of RCC disease and explore future directions. The overall landscape of RCC is promising, and we are confident that our update will stimulate further research in this field and contribute to the advancement of patient care. Renal cell cancer (RCC) has traditionally been considered radioresistant. Because of this, conventional radiotherapy (RT) has been predominantly relegated to the palliation of symptomatic metastatic disease. The implementation of stereotactic ablative radiotherapy (SABR) has made it possible to deliver higher ablative doses safely, shifting the renal radioresistance paradigm. SABR has increasingly been adopted into the multidisciplinary framework for the treatment of locally recurrent, oligoprogressive, and oligometastatic disease. Furthermore, there is growing evidence of SABR as a non-invasive definitive therapy in patients with primary RCC who are medically inoperable or who decline surgery, unsuited to invasive ablation (surgery or percutaneous techniques), or at high-risk of requiring post-operative dialysis. Encouraging outcomes have even been reported in cases of solitary kidney or pre-existing chronic disease (poor eGFR), with a high likelihood of preserving renal function. A review of clinical evidence supporting the use of ablative radiotherapy (SABR) in primary, recurrent, and metastatic RCC has been conducted. Given the potential immunogenic effect of the high RT doses, we also explore emerging opportunities to combine SABR with systemic treatments. In addition, we explore future directions and ongoing clinical trials in the evolving landscape of this disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Salvage Radiotherapy

Author

Perna, Carla, primary, Uribe, Jennifer, additional, Uribe-Lewis, Santiago, additional, and Langley, Stephen E. M., additional

Published
2020
Full Text
View/download PDF

15. Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts (PERSEUS1).

Author

Rescigno, Pasquale, Fenor de la Maza, Maria Dolores, Burnett, Stephanie M., Villacampa, Guillermo, Stiles, Morgaine, Cafferty, Fay Helen, Beije, Nick, Carreira, Suzanne, Figueiredo, Ines, Flohr, Penelope, Gurel, Bora, Bertan, Claudia, Westaby, Daniel, Chandran, Khobe, Crespo, Mateus, Perna, Carla, Tunariu, Nina, Sharp, Adam, Yap, Christina, and De Bono, Johann S.

Published
2024
Full Text
View/download PDF

16. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Author

Attard, Gerhardt, primary, Murphy, Laura, additional, Clarke, Noel W, additional, Sachdeva, Ashwin, additional, Jones, Craig, additional, Hoyle, Alex, additional, Cross, William, additional, Jones, Robert J, additional, Parker, Christopher C, additional, Gillessen, Silke, additional, Cook, Adrian, additional, Brawley, Chris, additional, Gilson, Clare, additional, Rush, Hannah, additional, Abdel-Aty, Hoda, additional, Amos, Claire L, additional, Murphy, Claire, additional, Chowdhury, Simon, additional, Malik, Zafar, additional, Russell, J Martin, additional, Parkar, Nazia, additional, Pugh, Cheryl, additional, Diaz-Montana, Carlos, additional, Pezaro, Carmel, additional, Grant, Warren, additional, Saxby, Helen, additional, Pedley, Ian, additional, O'Sullivan, Joe M, additional, Birtle, Alison, additional, Gale, Joanna, additional, Srihari, Narayanan, additional, Thomas, Carys, additional, Tanguay, Jacob, additional, Wagstaff, John, additional, Das, Prantik, additional, Gray, Emma, additional, Alzouebi, Mymoona, additional, Parikh, Omi, additional, Robinson, Angus, additional, Montazeri, Amir H, additional, Wylie, James, additional, Zarkar, Anjali, additional, Cathomas, Richard, additional, Brown, Michael D, additional, Jain, Yatin, additional, Dearnaley, David P, additional, Mason, Malcolm D, additional, Gilbert, Duncan, additional, Langley, Ruth E, additional, Millman, Robin, additional, Matheson, David, additional, Sydes, Matthew R, additional, Brown, Louise C, additional, Parmar, Mahesh K B, additional, James, Nicholas D, additional, Jones, Elin, additional, Hyde, Katherine, additional, Glen, Hilary, additional, Needleman, Sarah, additional, McGovern, Ursula, additional, Sheehan, Denise, additional, Paisey, Sangeeta, additional, Shaffer, Richard, additional, Beresford, Mark, additional, Porfiri, Emilio, additional, Fackrell, David, additional, Lee, Ling, additional, Sreenivasan, Thiagarajan, additional, Brock, Sue, additional, Brown, Simon, additional, Bahl, Amit, additional, Smith-Howell, Mike, additional, Woodward, Cathryn, additional, Phan, Mau-Don, additional, Mazhar, Danish, additional, Narahari, Krishna, additional, Douglas, Fiona, additional, Kumar, Anil, additional, Hamid, Abdel, additional, Ibrahim, Azman, additional, Muthukumar, Dakshinamoorthy, additional, Simms, Matthew, additional, Worlding, Jane, additional, Tran, Anna, additional, Kagzi, Mohammed, additional, Sivoglo, Virgil, additional, Masters, Benjamin, additional, Keng-Koh, Pek, additional, Manetta, Caroline, additional, McLaren, Duncan, additional, Gupta, Nishi, additional, Boussios, Stergios, additional, Taylor, Henry, additional, Graham, John, additional, Perna, Carla, additional, Melcher, Lucinda, additional, Sabharwal, Ami, additional, Hofmann, Uschi, additional, Dealey, Robert, additional, McPhail, Neil, additional, Brierly, Robert, additional, Capaldi, Lisa, additional, Sidek, Norma, additional, Whelan, Peter, additional, Robson, Peter, additional, Falconer, Alison, additional, Rudman, Sarah, additional, Vivekanandan, Sindu, additional, Mullessey, Vinod, additional, Vilarino-Varela, Maria, additional, Khoo, Vincent, additional, Tipples, Karen, additional, Afshar, Mehran, additional, Brulinski, Patryk, additional, Sangar, Vijay, additional, Peedell, Clive, additional, Azzabi, Ashraf, additional, Hoskin, Peter, additional, Mullassery, Viwod, additional, Sundar, Santhanam, additional, Khan, Yakhub, additional, Conroy, Ruth, additional, Protheroe, Andrew, additional, Carser, Judith, additional, Rogers, Paul, additional, Tarver, Kathryn, additional, Gibbs, Stephanie, additional, Khan, Mohammad Muneeb, additional, Hingorani, Mohan, additional, Crabb, Simon, additional, Alameddine, Manal, additional, Bhalla, Neeraj, additional, Hughes, Robert, additional, Logue, John, additional, Leaning, Darren, additional, Vengalil, Salil, additional, Ford, Daniel, additional, Walker, Georgina, additional, Shaheen, Ahmed, additional, Khan, Omar, additional, Chan, Andrew, additional, Ahmed, Imtiaz, additional, Hilman, Serena, additional, Sayers, Ian, additional, Nikapota, Ashok, additional, Bloomfield, David, additional, Porter, Tim, additional, Joseph, Joji, additional, Rentsch, Cyrill, additional, Pereira Mestre, Ricardo, additional, Roggero, Enrico, additional, Beyer, Jörg, additional, Borner, Markus, additional, Strebel, Raeto, additional, Berthold, Dominik, additional, Engeler, Daniel, additional, John, Hubert, additional, Popescu, Razvan, additional, and Durr, Donat, additional

Published
2023
Full Text
View/download PDF

17. Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial

Author

James, Nicholas D, primary, Ingleby, Fiona C, additional, Clarke, Noel W, additional, Amos, Claire L, additional, Attard, Gerhardt, additional, Brawley, Christopher D, additional, Chowdhury, Simon, additional, Cross, William, additional, Dearnaley, David P, additional, Gilbert, Duncan C, additional, Gillessen, Silke, additional, Jones, Robert J, additional, Langley, Ruth E, additional, Macnair, Archie, additional, Malik, Zafar I, additional, Mason, Malcolm D, additional, Matheson, David J, additional, Millman, Robin, additional, Parker, Chris C, additional, Rush, Hannah L, additional, Russell, J Martin, additional, Au, Carly, additional, Ritchie, Alastair W S, additional, Mestre, Ricardo Pereira, additional, Ahmed, Imtiaz, additional, Birtle, Alison J, additional, Brock, Susannah J, additional, Das, Prantik, additional, Ford, Victoria A, additional, Gray, Emma K, additional, Hughes, Robert J, additional, Manetta, Caroline B, additional, McLaren, Duncan B, additional, Nikapota, Ashok D, additional, O’Sullivan, Joe M, additional, Perna, Carla, additional, Peedell, Clive, additional, Protheroe, Andrew S, additional, Sundar, Santhanam, additional, Tanguay, Jacob S, additional, Tolan, Shaun P, additional, Wagstaff, John, additional, Wallace, Jan B, additional, Wylie, James P, additional, Zarkar, Anjali, additional, Parmar, Mahesh K B, additional, and Sydes, Matthew R, additional

Published
2022
Full Text
View/download PDF

19. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

Author

James, Nicholas D., Clarke, Noel W., Cook, Adrian, Ali, Adnan, Hoyle, Alex P., Attard, Gert, Brawley, Chris D., Chowdhury, Simon, Cross, William R., Dearnaley, David P., Bono, Johann S., Montana, Carlos Diaz, Gilbert, Duncan, Gillessen, Silke, Gilson, Clare, Jones, Rob J., Langley, Ruth E., Malik, Zafar I., Matheson, David J., Millman, Robin, Parker, Chris C., Pugh, Cheryl, Rush, Hannah, Russell, J. Martin, Berthold, Dominic R., Buckner, Michelle L., Mason, Malcolm D., Ritchie, Alastair W.S., Birtle, Alison J., Brock, Susannah J., Das, Prantik, Ford, Dan, Gale, Joanna, Grant, Warren, Gray, Emma K., Hoskin, Peter, Khan, Mohammad M., Manetta, Caroline, McPhail, Neil J., O'Sullivan, Joe M., Parikh, Omi, Perna, Carla, Pezaro, Carmel J., Protheroe, Andrew S., Robinson, Angus J., Rudman, Sarah M., Sheehan, Denise J., Srihari, Narayanan N., Syndikus, Isabel, Tanguay, Jacob, Thomas, Carys W., Vengalil, Salil, Wagstaff, John, Wylie, James P., Parmar, Mahesh K.B., and Sydes, Matthew R.

Subjects
Male, Cancer Research, Prednisolone, Abiraterone Acetate, Prostatic Neoplasms, Androgen Antagonists, B700, Hormones, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, Oncology, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, Humans, Prednisone, Aged, Follow-Up Studies, Retrospective Studies
Abstract

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multi-arm, multi-stage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients was planned for 3 yrs after the first results. Standard-of-care (SOC) was androgen deprivation therapy. The comparison randomized patients 1:1 to SOC-alone with or without daily abiraterone acetate 1000 mg + prednisolone 5 mg (SOC + AAP), continued until disease progression. The primary outcome measure was overall survival. Metastatic disease risk group was classified retrospectively using baseline CT and bone scans by central radiological review and pathology reports. Analyses used Cox proportional hazards & flexible parametric models, adjusted for baseline stratification factors. 1003 patients were contemporaneously randomized (Nov-2011--Jan-2014): median age 67 yr; 94% newly-diagnosed; metastatic disease risk group: 48% high, 44% low, 8% un-assessable; median PSA 97 ng/mL. At 6.1 yr median follow-up, 329 SOC-alone deaths (118 low-risk, 178 high-risk) and 244 SOC + AAP deaths (75 low-risk, 145 high-risk) were reported. Adjusted HR = 0·60 (95%CI:0·50—0·71; P = 0.31x10−9) favoured SOC + AAP, with 5-yr survival improved from 41% SOC-alone to 60% SOC + AAP. This was similar in low-risk (HR = 0·55; 95%CI:0·41—0·76) and high-risk (HR = 0·54; 95%CI:0·43—0·69) patients. Median and current maximum time on SOC + AAP was 2.4 yr and 8.1 yr. Toxicity at 4 yr post-randomisation was similar, with 16% patients in each group reporting grade 3 or higher toxicity. A sustained and substantial improvement in overall survival of all metastatic prostate cancer patients was achieved with SOC + abiraterone acetate + prednisolone, irrespective of metastatic disease risk group.\ud \ud This article is protected by copyright. All rights reserved.

Published
2022

20. Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

Author

Rush, Hannah L., primary, Murphy, Laura, additional, Morgans, Alicia K., additional, Clarke, Noel W., additional, Cook, Adrian D., additional, Attard, Gerhardt, additional, Macnair, Archie, additional, Dearnaley, David P., additional, Parker, Christopher C., additional, Russell, J. Martin, additional, Gillessen, Silke, additional, Matheson, David, additional, Millman, Robin, additional, Brawley, Christopher D., additional, Pugh, Cheryl, additional, Tanguay, Jacob S., additional, Jones, Robert J., additional, Wagstaff, John, additional, Rudman, Sarah, additional, O'Sullivan, Joe M., additional, Gale, Joanna, additional, Birtle, Alison, additional, Protheroe, Andrew, additional, Gray, Emma, additional, Perna, Carla, additional, Tolan, Shaun, additional, McPhail, Neil, additional, Malik, Zaf I., additional, Vengalil, Salil, additional, Fackrell, David, additional, Hoskin, Peter, additional, Sydes, Matthew R., additional, Chowdhury, Simon, additional, Gilbert, Duncan C., additional, Parmar, Mahesh K. B., additional, James, Nicholas D., additional, and Langley, Ruth E., additional

Published
2022
Full Text
View/download PDF

21. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Author

Attard, Gerhardt, primary, Murphy, Laura, additional, Clarke, Noel W, additional, Cross, William, additional, Jones, Robert J, additional, Parker, Christopher C, additional, Gillessen, Silke, additional, Cook, Adrian, additional, Brawley, Chris, additional, Amos, Claire L, additional, Atako, Nafisah, additional, Pugh, Cheryl, additional, Buckner, Michelle, additional, Chowdhury, Simon, additional, Malik, Zafar, additional, Russell, J Martin, additional, Gilson, Clare, additional, Rush, Hannah, additional, Bowen, Jo, additional, Lydon, Anna, additional, Pedley, Ian, additional, O'Sullivan, Joe M, additional, Birtle, Alison, additional, Gale, Joanna, additional, Srihari, Narayanan, additional, Thomas, Carys, additional, Tanguay, Jacob, additional, Wagstaff, John, additional, Das, Prantik, additional, Gray, Emma, additional, Alzoueb, Mymoona, additional, Parikh, Omi, additional, Robinson, Angus, additional, Syndikus, Isabel, additional, Wylie, James, additional, Zarkar, Anjali, additional, Thalmann, George, additional, de Bono, Johann S, additional, Dearnaley, David P, additional, Mason, Malcolm D, additional, Gilbert, Duncan, additional, Langley, Ruth E, additional, Millman, Robin, additional, Matheson, David, additional, Sydes, Matthew R, additional, Brown, Louise C, additional, Parmar, Mahesh K B, additional, James, Nicholas D, additional, Jones, Elin, additional, Hyde, Katherine, additional, Glen, Hilary, additional, Needleman, Sarah, additional, McGovern, Ursula, additional, Sheehan, Denise, additional, Paisey, Sangeeta, additional, Shaffer, Richard, additional, Beresford, Mark, additional, Porfiri, Emilio, additional, Fackrell, David, additional, Lee, Ling, additional, Sreenivasan, Thiagarajan, additional, Brock, Sue, additional, Brown, Simon, additional, Bahl, Amit, additional, Smith-Howell, Mike, additional, Woodward, Cathryn, additional, Phan, Mau-Don, additional, Mazhar, Danish, additional, Narahari, Krishna, additional, Douglas, Fiona, additional, Kumar, Anil, additional, Hamid, Abdel, additional, Ibrahim, Azman, additional, Muthukumar, Dakshinamoorthy, additional, Simms, Matthew, additional, Worlding, Jane, additional, Tran, Anna, additional, Kagzi, Mohammed, additional, Pezaro, Carmel, additional, Sivoglo, Virgil, additional, Masters, Benjamin, additional, Keng-Koh, Pek, additional, Manetta, Caroline, additional, McLaren, Duncan, additional, Gupta, Nishi, additional, Boussios, Stergios, additional, Taylor, Henry, additional, Graham, John, additional, Perna, Carla, additional, Melcher, Lucinda, additional, Grant, Warren, additional, Sabharwal, Ami, additional, Hofmann, Uschi, additional, Dealey, Robert, additional, McPhail, Neil, additional, Brierly, Robert, additional, Capaldi, Lisa, additional, Sidek, Norma, additional, Whelan, Peter, additional, Robson, Peter, additional, Falconer, Alison, additional, Rudman, Sarah, additional, Vivekanandan, Sindu, additional, Mullessey, Vinod, additional, Vilarino-Varela, Maria, additional, Khoo, Vincent, additional, Tipples, Karen, additional, Afshar, Mehran, additional, Brulinski, Patryk, additional, Sangar, Vijay, additional, Peedell, Clive, additional, Azzabi, Ashraf, additional, Hoskin, Peter, additional, Mullassery, Viwod, additional, Sundar, Santhanam, additional, Khan, Yakhub, additional, Conroy, Ruth, additional, Protheroe, Andrew, additional, Carser, Judith, additional, Rogers, Paul, additional, Tarver, Kathryn, additional, Gibbs, Stephanie, additional, Khan, Mohammad Muneeb, additional, Hingorani, Mohan, additional, Crabb, Simon, additional, Alameddine, Manal, additional, Bhalla, Neeraj, additional, Hughes, Robert, additional, Logue, John, additional, Leaning, Darren, additional, Vengalil, Salil, additional, Ford, Daniel, additional, Walker, Georgina, additional, Shaheen, Ahmed, additional, Khan, Omar, additional, Chan, Andrew, additional, Ahmed, Imtiaz, additional, Hilman, Serena, additional, Sayers, Ian, additional, Nikapota, Ashok, additional, Bloomfield, David, additional, Porter, Tim, additional, Joseph, Joji, additional, Rentsch, Cyrill, additional, Pereira Mestre, Ricardo, additional, Roggero, Enrico, additional, Beyer, Jörg, additional, Borner, Markus, additional, Strebel, Raeto, additional, Berthold, Dominik, additional, Engeler, Daniel, additional, John, Hubert, additional, Popescu, Razvan, additional, and Durr, Donat, additional

Published
2022
Full Text
View/download PDF

22. Robot Assisted Salvage Seminal Vesicle Excision for isolated recurrence after Low Dose Rate Prostate Brachytherapy

Author

Langley, Stephen, primary, Eden, Christopher, additional, Perry, Matthew, additional, Patil, Krishna, additional, Moschonas, Dimitrios, additional, Higgins, Donna, additional, Deering, Claire, additional, Laing, Robert, additional, Perna, Carla, additional, Khaksar, Sara, additional, Uribe‐Lewis, Santiago, additional, and Uribe, Jennifer, additional

Published
2021
Full Text
View/download PDF

24. In Regard to Parry et al

Author

Langley, Stephen, primary, Laing, Robert, additional, Khaksar, Sara, additional, Perna, Carla, additional, Otter, Sophie, additional, Mehta, Sheel, additional, Uribe-Lewis, Santiago, additional, and Uribe, Jennifer, additional

Published
2021
Full Text
View/download PDF

25. Predicting benefit of radium 223 based on biochemical response and site of metastasis: A real life multicenter UK study.

Author

Das, Prantik, primary, Davies, Jessica, additional, Sharma, Anand, additional, Nair, Ajith, additional, Vengalil, Salil, additional, Perna, Carla, additional, Branagan, Jenny, additional, Masters, Benjamin, additional, Goh, Chee, additional, Otter, Sophie, additional, Prakash, Vineet, additional, and Singh, Sadmeet, additional

Published
2021
Full Text
View/download PDF

26. Robot‐assisted salvage seminal vesicle excision for isolated recurrence after low‐dose‐rate prostate brachytherapy.

Author

Langley, Stephen, Eden, Christopher, Perry, Matthew, Patil, Krishna, Moschonas, Dimitrios, Higgins, Donna, Deering, Claire, Laing, Robert, Perna, Carla, Khaksar, Sara, Uribe‐Lewis, Santiago, and Uribe, Jennifer

Subjects
LOW dose rate brachytherapy, ENDORECTAL ultrasonography, SEMINAL vesicles, POSITRON emission tomography, SURGICAL margin, RADIOISOTOPE brachytherapy, ANDROGEN deprivation therapy
Abstract

Objectives: To report clinical and functional outcomes for patients who have undergone salvage robot‐assisted seminal vesicle excision (RA‐SVE) for the focal treatment of isolated seminal vesical (SV) recurrence after treatment for prostate cancer by low‐dose‐rate brachytherapy. Patients and Methods: Patients with rising prostate‐specific antigen (PSA) after low‐dose‐rate prostate brachytherapy (LDR‐PB) underwent multi‐parametric magnetic resonance imaging (mp‐MRI) of the prostate and 11C‐Choline or 68Ga‐prostate‐specific membrane antigen (68Ga‐PSMA) positron emission tomography/computed tomography (PET/CT) scan, followed by targeted transperineal biopsy of the prostate and SVs. Isolated SV recurrence were identified in 17 (0.38%) LDR‐PB patients. These 17 patients were offered RA‐SVE. Results: The median total operative time was 90 min and blood loss 50 mL with no postoperative transfusions required. The median hospital stay was 1 day. No intra‐ or postoperative complications were documented. Continence status was unaffected, no patient required urinary pads. Postoperative pathology confirmed SV invasion in all specimens. Surgical margins were positive in seven (41%) patients. All patients had at least one positive imaging study, although three (18%) mp‐MRI and five (29%) PET/CT assessments were negative. One (6%) pre‐SVE biopsy was also negative but with positive imaging. Salvage SVE failure, defined as three consecutive PSA rises or the need for further treatment, occurred in six patients of whom three had a positive margin. Overall failure‐free survival rates were 86%, 67%, and 53% at 1, 2, and 3 years after SVE, respectively. Conclusions: Salvage RA‐SVE appears to be a safe focal treatment, with very low morbidity, for patients with localised SV recurrence after LDR‐PB. It permits deferral of androgen deprivation therapy in selected patients. Bilateral SVE is mandatory. This surgical option should be considered in patients with isolated prostate cancer recurrence to the SV. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. Long‐term survival after low‐dose‐rate brachytherapy for prostate cancer: the Royal Surrey experience.

Author

Uribe‐Lewis, Santiago, Uribe, Jennifer, Bourke, Vincent, Deering, Claire, Higgins, Donna, Mehta, Sheel, Mikropoulos, Christos, Otter, Sophie, Perna, Carla, Khaksar, Sara, Laing, Robert, and Langley, Stephen

Subjects
PROSTATE cancer, RADIOISOTOPE brachytherapy, LOW dose rate brachytherapy, ANDROGEN deprivation therapy, EXTERNAL beam radiotherapy, PROSTATE-specific antigen
Abstract

Objectives: To assess the long‐term treatment efficacy of low‐dose‐rate (LDR) brachytherapy for the treatment of localized prostate cancer. Patients and Methods: Cause‐of‐death annotation in our prospective database was supplemented with death certificate information obtained via an internal audit of patients treated from 1999 to 2017 with LDR prostate brachytherapy as monotherapy or as combination with androgen deprivation therapy and/or external beam radiotherapy. Overall and disease‐specific survival were the primary outcomes, estimated with Kaplan–Meier and competing risks multi‐state models. Clinical variables influencing mortality were assessed with Cox proportional hazards regression in a sub‐analysis of men to assess the predictive value of prostate‐specific antigen (PSA) level at 48 months post implant. Results: The audit process began in October 2017 and culminated in June 2020 with a curated series of 2936 patients. All‐cause and prostate cancer‐specific death prevalence were 11% and 2.9%, respectively. The median (range) follow‐up time was 10 (3–21) years and the median (range) time to death from any cause was 9 (3–21) years. At 15 years post implant the overall and prostate cancer‐specific survival probability were 81% and 95%, respectively. The 15‐year cumulative incidence rates of death not due and due to prostate cancer were 14% and 5%, respectively. A greater risk of death due to prostate cancer was conferred by increasing age at therapy (hazard ratio [HR] 1.1, P < 0.001), advanced clinical stages relative to T1a‐T2a (HR 1.9, P = 0.048 for T2b; HR 2.7, P = 0.023 for T2c‐T3b) and a 48‐month PSA level >1.0 ng/mL (HR 6.8, P < 0.001). Conclusion: This study constitutes the largest retrospective analyses of long‐term mortality outcomes from prospectively collected prostate brachytherapy data and confirms the excellent treatment efficacy of LDR prostate brachytherapy for localized prostate cancer. T2 clinical stage subdivisions and 48‐month PSA level >1.0 ng/mL appear to be strong indicators of prostate cancer‐related survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials

Author

Bamman, Marcas M., primary, Cutter, Gary R., additional, Brienza, David M., additional, Chae, John, additional, Corcos, Daniel M., additional, DeLuca, Stephanie, additional, Field-Fote, Edelle, additional, Fouad, Mona N., additional, Lang, Catherine E., additional, Lindblad, Anne, additional, Motl, Robert W., additional, Perna, Carla G., additional, Reisman, Darcy, additional, Saag, Kenneth M., additional, Savitz, Sean I., additional, Schmitz, Kathryn H, additional, Stevens-Lapsley, Jennifer, additional, Whyte, John, additional, Winstein, Carolee J., additional, and Michel, Mary E., additional

Published
2018
Full Text
View/download PDF

32. Hemi‐ablative low‐dose‐rate prostate brachytherapy for unilateral localised prostate cancer.

Author

Langley, Stephen, Uribe, Jennifer, Uribe‐Lewis, Santiago, Franklin, Adrian, Perna, Carla, Horton, Alex, Cunningham, Melanie, Higgins, Donna, Deering, Claire, Khaksar, Sara, and Laing, Robert

Subjects
PROSTATE cancer, RADIOISOTOPE brachytherapy, PROSTATE, PROSTATE-specific antigen, REGRESSION analysis
Abstract

Objectives: To report clinical outcomes of the Hemi‐Ablative Prostate Brachytherapy (HAPpy) trial evaluating treatment‐related toxicity and effectiveness of hemi‐gland (HG) low‐dose‐rate (LDR) prostate brachytherapy as a focal approach to control unilateral localised prostate cancer. Patients and Methods: Single institution phase IIS pilot study of patients treated with focal 4D Brachytherapy™ (BXTAccelyon, Burnham, Buckinghamshire, UK). The primary outcome was patient‐reported toxicity 24 months after implant. The secondary outcome was assessment of disease control. Outcomes in HG patients were compared to whole‐gland (WG) controls obtained from our prospective cohort registry by negative binomial and linear regression models. Results: Pre‐treatment demography was similar between the 30 HG patients and 362 WG controls. Post‐implant dosimetry was similar for the prostate gland target volumes and significantly reduced for the urethra and bowel in HG patients relative to WG controls, but this did not translate into a difference in post‐implant mean symptom scores between the two groups. Nevertheless, the change in score from baseline indicated that the impact on pre‐treatment symptom status was less after HG implants. Only HG patients showed a return to baseline urinary scores as early as 12 months. Sexual potency was conserved in 73% and 67% of HG and WG patients, respectively (P = 0.84). Post‐implant prostate‐specific antigen (PSA) kinetics revealed that baseline PSA was reduced at 24 months by 78% and 88% in HG and WG patients, respectively (P < 0.05). Treatment relapse occurred in one (3%) HG patient 55 months after implant and in nine (3%) WG patients at 32–67 months after implant. Conclusion: This pilot study suggests that treatment‐related toxicity and biochemical outcomes after HG implants are broadly similar to those observed with WG treatment despite the lower dose delivered by HG implants. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

36. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Author

James ND, Clarke NW, Cook A, Ali A, Hoyle AP, Attard G, Brawley CD, Chowdhury S, Cross WR, Dearnaley DP, de Bono JS, Diaz-Montana C, Gilbert D, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Matheson DJ, Millman R, Parker CC, Pugh C, Rush H, Russell JM, Berthold DR, Buckner ML, Mason MD, Ritchie AWS, Birtle AJ, Brock SJ, Das P, Ford D, Gale J, Grant W, Gray EK, Hoskin P, Khan MM, Manetta C, McPhail NJ, O'Sullivan JM, Parikh O, Perna C, Pezaro CJ, Protheroe AS, Robinson AJ, Rudman SM, Sheehan DJ, Srihari NN, Syndikus I, Tanguay JS, Thomas CW, Vengalil S, Wagstaff J, Wylie JP, Parmar MKB, and Sydes MR

Subjects
Abiraterone Acetate therapeutic use, Aged, Androgen Antagonists therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Follow-Up Studies, Hormones, Humans, Male, Prednisolone therapeutic use, Prednisone therapeutic use, Retrospective Studies, Treatment Outcome, Prostatic Neoplasms pathology, Prostatic Neoplasms, Castration-Resistant drug therapy
Abstract

Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial in men starting long-term hormone therapy for prostate cancer. This long-term analysis in metastatic patients was planned for 3 years after the first results. Standard-of-care (SOC) was androgen deprivation therapy. The comparison randomised patients 1:1 to SOC-alone with or without daily abiraterone acetate 1000 mg + prednisolone 5 mg (SOC + AAP), continued until disease progression. The primary outcome measure was overall survival. Metastatic disease risk group was classified retrospectively using baseline CT and bone scans by central radiological review and pathology reports. Analyses used Cox proportional hazards and flexible parametric models, accounting for baseline stratification factors. One thousand and three patients were contemporaneously randomised (November 2011 to January 2014): median age 67 years; 94% newly-diagnosed; metastatic disease risk group: 48% high, 44% low, 8% unassessable; median PSA 97 ng/mL. At 6.1 years median follow-up, 329 SOC-alone deaths (118 low-risk, 178 high-risk) and 244 SOC + AAP deaths (75 low-risk, 145 high-risk) were reported. Adjusted HR = 0.60 (95% CI: 0.50-0.71; P = 0.31 × 10 -9 ) favoured SOC + AAP, with 5-years survival improved from 41% SOC-alone to 60% SOC + AAP. This was similar in low-risk (HR = 0.55; 95% CI: 0.41-0.76) and high-risk (HR = 0.54; 95% CI: 0.43-0.69) patients. Median and current maximum time on SOC + AAP was 2.4 and 8.1 years. Toxicity at 4 years postrandomisation was similar, with 16% patients in each group reporting grade 3 or higher toxicity. A sustained and substantial improvement in overall survival of all metastatic prostate cancer patients was achieved with SOC + abiraterone acetate + prednisolone, irrespective of metastatic disease risk group., (© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results